Geoffrey Porges, an analyst at Sanford C. Bernstein -- mentioned in a forbes article on dendreon and their cancer drug, provenge:
"It’s hard to understate how tough Porges wound up being on Provenge. He writes that Provenge is likely to achieve peak sales of $450 million, and that it won’t hit that peak until 2021. At that point, if expenses were kept flat, the company would be only marginally profitable."
now why exactly do you think this is a great buy?